Graphy Publications
Inspiring Innovations & Discoveries
International Journal of Clinical & Medical Microbiology Volume 1 (2016), Article ID 1:IJCMM-101, 2 pages
https://doi.org/10.15344/2456-4028/2016/101
Commentary
A Putative Fifth Serotype of Dengue - Potential Implications for Diagnosis, Therapy and Vaccine Design

Andrew W. Taylor-Robinson

School of Medical & Applied Sciences, Central Queensland University, Rockhampton, QLD 4702, Australia
Prof Andrew W. Taylor-Robinson, School of Medical & Applied Sciences, Central Queensland University, Bruce Highway, Rockhampton, QLD 4702, Australia. Tel: +61 7 4923 2008; E-mail: a.taylor-robinson@cqu.edu.au
08 December 2015; 28 February 2016; 03 March 2016
Taylor-Robinson AW (2016) A Putative Fifth Serotype of Dengue - Potential Implications for Diagnosis, Therapy and Vaccine Design. Int J Clin Med Microbiol 1: 101. doi: https://doi.org/10.15344/2456-4028/2016/101

Abstract

Dengue is now established as the world’s most important arboviral infection. This Aedes mosquitotransmitted pathogen is considered to be the cause of a major re-emerging tropical disease and significant public health concern. Four distinct but genetically similar serotypes of dengue virus, DENV 1-4, are responsible for provoking a spectrum of clinical symptoms in humans that range from mild fever to severe haemorrhagic manifestations. Recently, a phylogenetically more distant fifth serotype has been mooted. Confirmation of the identification of this virus is required before its status as DENV-5 can be formally recognized. Nevertheless, the possibility of a further serotype raises the spectre of those antidengue therapies and vaccines predicated on DENV 1-4 that are currently under clinical trial being intrinsically suboptimal. Hence, the potential impact of the existence of DENV-5 and other sylvatic arboviruses on the strategy to combat dengue fever and related pyrexias of unknown origin should be considered in order to refine guidelines for diagnosis, treatment, prevention and control.